The question matters to me because my employer, Gilead Sciences, is the leading manufacturer of both HIV and hepatitis C (HCV) medicines. In the 2000s, unprecedented global advocacy for HIV treatment led directly to progress on these three key fronts in the 2000s. Together, they account for the large majority of people on antiretroviral therapy in developing countries today, more than 19.5 million in low- and middle-income countries. But we can’t recreate the unique HIV treatment access landscape of the 2000s. The modeling showed that, in 67 low-income and middle-income countries, more than 75% of costs are for health systems with health workforces, with infrastructure as the main cost drivers.

Source: Forbes October 27, 2017 14:15 UTC